Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC

BACKGROUND: Nivolumab is an immune checkpoint inhibitor targeting the programmed death-1 receptor that improves survival in a subset of patients with clear cell renal cell carcinoma (ccRCC). In contrast to other tumor types that respond to immunotherapy, factors such as programmed death ligand-1 (PD...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Immunother Cancer
Päätekijät: Ross-Macdonald, Petra, Walsh, Alice M, Chasalow, Scott D, Ammar, Ron, Papillon-Cavanagh, Simon, Szabo, Peter M, Choueiri, Toni K, Sznol, Mario, Wind-Rotolo, Megan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2021
Aiheet:
Clinical/Translational Cancer Immunotherapy
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7931766/
https://ncbi.nlm.nih.gov/pubmed/33658305
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001506
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia